KR102599718B1 - 표적 엔티티 검출을 위한 시스템, 조성물 및 방법 - Google Patents

표적 엔티티 검출을 위한 시스템, 조성물 및 방법 Download PDF

Info

Publication number
KR102599718B1
KR102599718B1 KR1020217031580A KR20217031580A KR102599718B1 KR 102599718 B1 KR102599718 B1 KR 102599718B1 KR 1020217031580 A KR1020217031580 A KR 1020217031580A KR 20217031580 A KR20217031580 A KR 20217031580A KR 102599718 B1 KR102599718 B1 KR 102599718B1
Authority
KR
South Korea
Prior art keywords
delete delete
target
cancer
detection
entity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217031580A
Other languages
English (en)
Korean (ko)
Other versions
KR20210141952A (ko
Inventor
조셉 찰스 세들락
로라 테레사 보톨린
다니엘 파커 세일럼
Original Assignee
메르시 바이오애널리틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르시 바이오애널리틱스, 인코포레이티드 filed Critical 메르시 바이오애널리틱스, 인코포레이티드
Publication of KR20210141952A publication Critical patent/KR20210141952A/ko
Application granted granted Critical
Publication of KR102599718B1 publication Critical patent/KR102599718B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/501—Ligase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/101—Reactions characterised by their quantitative nature the purpose being quantitative analysis with an internal standard/control
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020217031580A 2019-03-01 2020-02-28 표적 엔티티 검출을 위한 시스템, 조성물 및 방법 Active KR102599718B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962812878P 2019-03-01 2019-03-01
US62/812,878 2019-03-01
US202062962722P 2020-01-17 2020-01-17
US62/962,722 2020-01-17
PCT/US2020/020529 WO2020180741A1 (en) 2019-03-01 2020-02-28 Systems, compositions, and methods for target entity detection

Publications (2)

Publication Number Publication Date
KR20210141952A KR20210141952A (ko) 2021-11-23
KR102599718B1 true KR102599718B1 (ko) 2023-11-09

Family

ID=72338354

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031580A Active KR102599718B1 (ko) 2019-03-01 2020-02-28 표적 엔티티 검출을 위한 시스템, 조성물 및 방법

Country Status (9)

Country Link
US (3) US11085089B2 (enExample)
EP (2) EP3998349A3 (enExample)
JP (1) JP7344973B2 (enExample)
KR (1) KR102599718B1 (enExample)
CN (1) CN113748217B (enExample)
AU (2) AU2020233286B2 (enExample)
CA (1) CA3129868A1 (enExample)
SG (1) SG11202109423TA (enExample)
WO (1) WO2020180741A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7344973B2 (ja) 2019-03-01 2023-09-14 マーシー バイオアナリティクス， インコーポレイテッド 標的実体を検出するためのシステム、組成物、及び方法
US20250326855A1 (en) 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CA3227148A1 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of colorectal cancer
CA3227124A1 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of pancreatic cancer
US20240369558A1 (en) * 2021-07-21 2024-11-07 Mercy Bioanalytics, Inc. Compositions and methods for detection of breast cancer
US20250043357A1 (en) * 2021-07-21 2025-02-06 Mercy Bioanalytics, Inc. Compositions and methods for detection of esophageal cancer
WO2023004083A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for detection of bile duct cancer
EP4373860A4 (en) * 2021-07-21 2025-05-21 Mercy Bioanalytics, Inc. COMPOSITIONS AND METHODS FOR THE DETECTION OF PROSTATE CANCER
WO2023004087A2 (en) * 2021-07-21 2023-01-26 Mercy Bioanalytics, Inc. Compositions and methods for cancer detection
US20250297317A1 (en) * 2021-07-21 2025-09-25 Mercy Bioanalytics, Inc. Compositions and methods for detection of liver cancer
KR20240107093A (ko) 2021-08-05 2024-07-08 고 테라퓨틱스, 인크. 항-글리코-muc4 항체 및 그의 용도
US20250066498A1 (en) 2021-09-03 2025-02-27 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
JP2024536722A (ja) 2021-09-03 2024-10-08 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｍｅｔ抗体およびその使用
CN120584193A (zh) * 2022-11-23 2025-09-02 润知生物技术公司 用于蛋白质分析物的检测的组合物和方法
WO2025252658A1 (en) 2024-06-03 2025-12-11 Olink Proteomics Ab New product and method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246792A1 (en) 1999-06-17 2009-10-01 Becton, Dickinson And Company Methods for detecting nucleic acid sequence variations
WO2015188192A3 (en) 2014-06-06 2016-05-26 Cornell University Method for identification and enumeration of nucleic acid sequence, expression, copy, or dna methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions
WO2017214127A1 (en) 2016-06-06 2017-12-14 Redvault Biosciences, Lp Target reporter constructs and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795714A (en) * 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
CA2118759C (en) 1993-04-21 2004-06-22 William Jeffrey Allard Diagnosis and monitoring of lung cancer patients by measurement of nca 50/90 in blood
US7306904B2 (en) 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
EP1451356A1 (en) 2001-11-23 2004-09-01 Simon Fredriksson Method and kit for proximity probing with multivalent proximity probes
EP1615948B1 (en) 2003-04-18 2015-04-01 Becton Dickinson and Company Immuno-amplification
EP1633888B1 (en) 2003-06-17 2009-03-25 Keygene N.V. Means and method for the detection of target nucleotide sequences using ligation assays with improved oligonucleotide probe pairs
WO2005123963A2 (en) 2004-06-14 2005-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in analyte detection using proximity probes
GB0605584D0 (en) 2006-03-20 2006-04-26 Olink Ab Method for analyte detection using proximity probes
US8758991B2 (en) 2006-04-26 2014-06-24 University Of Louisville Research Foundation, Inc. Isolation of membrane vesicles from biological fluids and methods of using same
JP5580205B2 (ja) 2007-11-19 2014-08-27 セレラ コーポレーション 肺癌マーカーとその使用
US8481698B2 (en) 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
GB201004292D0 (en) 2010-03-15 2010-04-28 Olink Ab Assay for localised detection of analytes
WO2012049316A1 (en) 2010-10-15 2012-04-19 Olink Ab Dynamic range methods
JP6219721B2 (ja) 2010-11-10 2017-10-25 エキソソーム ダイアグノスティックス インコーポレイテッド 核酸含有粒子の単離および該粒子からの核酸の抽出のための方法
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
ES2744589T3 (es) 2011-05-11 2020-02-25 Exosome Diagnostics Inc Extracción de ácido nucleico de materiales biológicos heterogéneos
AU2012255121B2 (en) * 2011-05-17 2017-03-09 Dxterity Diagnostics Incorporated Methods and compositions for detecting target nucleic acids
GB201108678D0 (en) 2011-05-24 2011-07-06 Olink Ab Multiplexed proximity ligation assay
EP2776587A4 (en) 2011-11-10 2015-07-15 Exosome Diagnostics Inc LIQUOR ASSAY
US9029086B2 (en) 2012-01-26 2015-05-12 Masood Kamali Moghaddam Detection of single and multimodal analytes
WO2014015149A2 (en) 2012-07-18 2014-01-23 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
US20150252428A1 (en) 2012-10-03 2015-09-10 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
WO2014076214A1 (en) 2012-11-14 2014-05-22 Olink Ab Rca reporter probes and their use in detecting nucleic acid molecules
EP2920324B1 (en) 2012-11-14 2017-12-27 Olink Bioscience AB Localised rca-based amplification method
US9086412B2 (en) 2012-12-31 2015-07-21 University Of Louisville Research Foundation, Inc. Extracellular vesicle-associated protein markers of cancer
US20150353920A1 (en) 2013-01-03 2015-12-10 Exosome Diagnostics, Inc. Methods for isolating microvesicles
BR112016002716B1 (pt) 2013-08-06 2023-02-28 Exosome Diagnostics, Inc Método para diagnóstico ou monitoramento de um progresso ou recorrência de um câncer de próstata com escore de gleason alto
BR112016004153A2 (pt) * 2013-08-28 2019-09-17 Caris Life Sciences Switzerland Holdings Gmbh "método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero
US10633691B2 (en) 2013-09-30 2020-04-28 Di Wu Methods to profile molecular complexes or single cells via proximity dependant barcoding
GB201401885D0 (en) 2014-02-04 2014-03-19 Olink Ab Proximity assay with detection based on hybridisation chain reaction (HCR)
WO2015130956A2 (en) 2014-02-28 2015-09-03 Exosome Sciences, Inc. Brain specific exosome based diagnostics and extracorporeal therapies
CN119709943A (zh) * 2014-05-15 2025-03-28 中尺度技术有限责任公司 改进的测定方法
WO2015193427A1 (en) 2014-06-19 2015-12-23 Olink Ab Determination and analysis of biomarkers in clinical samples
JP2017537657A (ja) * 2014-12-11 2017-12-21 ニユー・イングランド・バイオレイブス・インコーポレイテツド 標的配列の濃縮
US11175286B2 (en) * 2015-01-09 2021-11-16 Spot Biosystems Ltd. Immunolipoplex nanoparticle biochip containing molecular probes for capture and characterization of extracellular vesicles
US20180066262A1 (en) * 2015-03-09 2018-03-08 Caris Science, Inc. Oligonucleotide probes and uses thereof
JP6921809B2 (ja) * 2015-09-22 2021-08-18 トラスティーズ オブ ボストン ユニバーシティ ナノ小胞の多重表現型決定法
GB201518655D0 (en) 2015-10-21 2015-12-02 Olink Ab Method for generating proximity probes
US10526665B2 (en) * 2016-03-04 2020-01-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis
EP3548635B1 (en) * 2016-11-30 2021-04-28 Exosome Diagnostics, Inc. Methods to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients
WO2018119455A1 (en) 2016-12-23 2018-06-28 Exosome Diagnostics, Inc. Biofluid analysis and quantitation systems and methods
US11899024B2 (en) * 2017-07-12 2024-02-13 Exosome Diagnostics, Inc. Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles
WO2019018537A1 (en) 2017-07-18 2019-01-24 Exosome Diagnostics, Inc. NUCLEIC ACID SEQUENCING ASSOCIATED WITH EXOSOMAL ISOLATION IN PATIENTS WITH MULTIPLE GLIOBLASTOMA
JP2020528766A (ja) 2017-07-26 2020-10-01 ロゼッタ エクソソーム 陽イオンを利用した細胞外小胞体の分離方法
WO2019022542A2 (ko) 2017-07-26 2019-01-31 ㈜로제타엑소좀 양이온을 이용한 세포밖 소포체의 분리 방법
WO2019066501A1 (ko) 2017-09-27 2019-04-04 ㈜로제타엑소좀 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분석 방법 및 이의 용도
WO2019103548A2 (ko) 2017-11-24 2019-05-31 ㈜로제타엑소좀 반건식 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 분리 방법
WO2019113499A1 (en) * 2017-12-07 2019-06-13 The Broad Institute, Inc. High-throughput methods for identifying gene interactions and networks
EP3793715A2 (en) * 2018-05-17 2021-03-24 Meso Scale Technologies, LLC Methods for isolating surface marker displaying agents
EP3802884B1 (en) 2018-06-06 2024-12-25 Exosome Diagnostics, Inc. Methods for developing urine biomarkers and for detecting bladder cancer
WO2019238944A1 (en) 2018-06-15 2019-12-19 Olink Proteomics Ab Biomarker panel for ovarian cancer
EP3870348A1 (en) * 2018-10-23 2021-09-01 Meso Scale Technologies, LLC Methods for isolating surface marker displaying agents
WO2020106853A1 (en) 2018-11-20 2020-05-28 Exosome Diagnostics, Inc. Compositions and methods for internal controls of microvesicle isolations
JP7344973B2 (ja) 2019-03-01 2023-09-14 マーシー バイオアナリティクス， インコーポレイテッド 標的実体を検出するためのシステム、組成物、及び方法
JP2023510911A (ja) * 2020-01-17 2023-03-15 マーシー バイオアナリティクス， インコーポレイテッド 卵巣癌を検出するための組成物及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246792A1 (en) 1999-06-17 2009-10-01 Becton, Dickinson And Company Methods for detecting nucleic acid sequence variations
WO2015188192A3 (en) 2014-06-06 2016-05-26 Cornell University Method for identification and enumeration of nucleic acid sequence, expression, copy, or dna methylation changes, using combined nuclease, ligase, polymerase, and sequencing reactions
WO2017214127A1 (en) 2016-06-06 2017-12-14 Redvault Biosciences, Lp Target reporter constructs and uses thereof

Also Published As

Publication number Publication date
EP3998349A3 (en) 2022-08-24
WO2020180741A1 (en) 2020-09-10
EP3931351A1 (en) 2022-01-05
US11085089B2 (en) 2021-08-10
US20200299780A1 (en) 2020-09-24
EP3931351B1 (en) 2024-09-11
EP3931351A4 (en) 2022-05-11
JP7344973B2 (ja) 2023-09-14
US20220155304A1 (en) 2022-05-19
KR20210141952A (ko) 2021-11-23
AU2022241629B2 (en) 2025-05-29
AU2022241629A1 (en) 2022-10-27
US20210214806A1 (en) 2021-07-15
CA3129868A1 (en) 2020-09-10
CN113748217A (zh) 2021-12-03
AU2020233286A1 (en) 2021-10-14
JP2022521781A (ja) 2022-04-12
CN113748217B (zh) 2023-08-25
AU2020233286B2 (en) 2022-10-20
SG11202109423TA (en) 2021-09-29
EP3998349A2 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
KR102599718B1 (ko) 표적 엔티티 검출을 위한 시스템, 조성물 및 방법
KR20220129591A (ko) 난소암의 검출을 위한 조성물 및 방법
KR20230044429A (ko) 폐암의 검출을 위한 조성물 및 방법
WO2023004083A2 (en) Compositions and methods for detection of bile duct cancer
WO2023004079A2 (en) Compositions and methods for detection of liver cancer
US20240377401A1 (en) Compositions and methods for detection of prostate cancer
US20240369560A1 (en) Compositions and methods for detection of pancreatic cancer
US20240344139A1 (en) Compositions and methods for detection of colorectal cancer
HK40076883A (en) Compositions and methods for target protein detection on exosomes using proximal ligation
HK40066670B (en) Method for target entity detection using ligase
US20250327129A1 (en) Compositions and methods for detection of ovarian cancer
HK40066670A (en) Method for target entity detection using ligase

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601